Sweden's Integrum Q3 sales fall 14.8% yr/yr

Integrum AB

05/03/2026 06:55

Overview

Swedish osseointegration implant firm's Q3 sales fell 14.8% yr/yr, but rose 6.3% in constant currency

Company completed rights issue, raising SEK 42.7 mln

Company implemented organizational changes for increased efficiency and cost control

Outlook

Integrum focuses on growth and profitability after structural transformation

Company aims to accelerate commercialization of OPRA Implant System in US

Result Drivers

RIGHTS ISSUE - Integrum completed a rights issue oversubscribed by 351%, raising SEK 42.7 mln

US GOVERNMENT SHUTDOWN - Unusually long federal government shutdown in the US delayed decisions affecting sales

Company press release: ID:nWkr1F457J

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
SEK 20.20 mln


Analyst Coverage

Wall Street's median 12-month price target for Integrum AB is SEK32.58, about 302.3% above its March 4 closing price of SEK8.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)